Efficacy and safety of ripretinib in Chinese patients with advanced gastrointestinal stromal tumors (GIST) as ≥4th line therapy: Long-term update from a single-arm, phase 2 trial

被引：0
|
作者：
Li, Jian
Zhang, Xinhua
Zhou, Yongjian
Zhang, Jun
Zhou, Ye
Wang, Ming
Wu, Xin
Deng, Yanhong
Huang, Zhao
Dong, Juan
Shen, Lin
机构：
[1] Peking Univ Canc Hosp & Inst, Beijing, Peoples R China
[2] Sun Yat Sen Univ, Affiliated Hosp 1, Guangzhou, Peoples R China
[3] Fujian Med Univ, Union Hosp, Fuzhou, Peoples R China
[4] Chongqing Med Univ, Affiliated Hosp 1, Chongqing, Peoples R China
[5] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China
[6] Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Shanghai, Peoples R China
[7] Chinese Peoples Liberat Army Gen Hosp, Beijing, Peoples R China
[8] Sun Yat Sen Univ, Affiliated Hosp 6, Guangzhou, Peoples R China
[9] Zai Lab Shanghai Co Ltd, R&D Dept, Shanghai, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
11543
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Clinical benefit with ripretinib as ≥4th line treatment in patients with advanced gastrointestinal stromal tumors (GIST): Update from the phase III INVICTUS study
    Zalcberg, J. R.
    Heinrich, M.
    George, S.
    Bauer, S.
    Gelderblom, H.
    Schoffski, P.
    Serrano, C.
    Jones, R. L.
    Attia, S.
    D'Amato, G.
    Chi, P.
    Reichardt, P.
    Meade, J. N.
    Reichert, V.
    Shi, K.
    Ruiz-Soto, R.
    von Mehren, M.
    Blay, J-Y.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 : S973 - S974
  • [2] Clinical benefit with ripretinib as ≥4th line treatment in patients with advanced gastrointestinal stromal tumors (GIST): Update from the phase III INVICTUS study
    Bauer, S.
    Heinrich, M.
    George, S.
    Zalcberg, J. R.
    Gelderblom, H.
    Schoffski, P.
    Serrano, C.
    Jones, R. L.
    Attia, S.
    D'Amato, G.
    Chi, P.
    Reichardt, P.
    Meade, J. N.
    Reichert, V
    Shi, K.
    Ruiz-Soto, R.
    von Mehren, M.
    Blay, J. -Y.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 11 - 11
  • [3] Efficacy and Safety of Ripretinib in Chinese Patients with Advanced Gastrointestinal Stromal Tumors as a Fourth- or Later-Line Therapy: A Multicenter, Single-Arm, Open-Label Phase II Study
    Li, Jian
    Cai, Shirong
    Zhou, Yongjian
    Zhang, Jun
    Zhou, Ye
    Cao, Hui
    Wu, Xin
    Deng, Yanhong
    Huang, Zhao
    Dong, Juan
    Shen, Lin
    [J]. CLINICAL CANCER RESEARCH, 2022, 28 (16) : 3425 - 3432
  • [4] Ripretinib as ≥4th-line treatment in patients with advanced gastrointestinal stromal tumor: Long-term update from the phase III INVICTUS study
    von Mehren, M.
    Heinrich, C.
    George, S.
    Zalcberg, J. R.
    Bauer, S.
    Gelderblom, H.
    Schoffski, P.
    Serrano, C.
    Jones, R. L.
    Attia, S.
    D'Amato, G.
    Chi, P.
    Reichardt, P.
    Meade, J. N.
    Reichert, V. L.
    Shi, K.
    Ruiz-Soto, R.
    Blay, J-Y.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S1120 - S1121
  • [5] Long-term safety of regorafenib (REG) in advanced gastrointestinal stromal tumors (GIST): updated safety data of the phase 3 GRID trial
    Demetri, G. D.
    Reichardt, P.
    Kang, Y-K.
    Blay, J-Y.
    Joensuu, H.
    Kappeler, C.
    Wuchter-Czerwony, C.
    Chung, J.
    Wagner, A.
    Casali, P. G.
    [J]. ANNALS OF ONCOLOGY, 2016, 27
  • [6] Safety and efficacy of dasatinib in patients with advanced gastrointestinal stromal tumors refractory to imatinib and sunitinib: A single arm, multicenters, phase 2 trial.
    Li, Jian
    Zhou, Ye
    Zhang, Xinhua
    Wu, Xiaojun
    Zhou, Yongjian
    Liu, Xiufeng
    Zhang, Bo
    Wu, Xin
    Lin, Shen
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [7] Efficacy and safety of ripretinib as ≥4th-line therapy for patients with gastrointestinal stromal tumor following crossover from placebo: Analyses from INVICTUS
    Serrano, C.
    Heinrich, M.
    George, S.
    Zalcberg, J.
    Bauer, S.
    Gelderblom, H.
    Schoffski, P.
    Jones, R.
    Attia, S.
    D'Amato, G.
    Chi, P.
    Reichardt, P.
    Meade, J.
    Reichert, V.
    Shi, K.
    Blay, J.
    von Mehren, M.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 : S236 - S236
  • [8] Efficacy and safety of anlotinib in patients with advanced malignancy: a single-center, single-arm, phase 2 trial
    Yihebali Chi
    Guangqian Ji
    Jing Zhang
    Haijian Tang
    Yang Yang
    Wei Liu
    Nan Wang
    Chunhui Gao
    Yongkun Sun
    Jinwan Wang
    [J]. International Journal of Clinical Oncology, 2021, 26 : 1611 - 1618
  • [9] Efficacy and safety of anlotinib in patients with advanced malignancy: a single-center, single-arm, phase 2 trial
    Chi, Yihebali
    Ji, Guangqian
    Zhang, Jing
    Tang, Haijian
    Yang, Yang
    Liu, Wei
    Wang, Nan
    Gao, Chunhui
    Sun, Yongkun
    Wang, Jinwan
    [J]. INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2021, 26 (09) : 1611 - 1618
  • [10] Impact of mutational status on long-term treatment outcomes in patients with advanced gastrointestinal stromal tumors (GIST) treated in the first line with imatinib
    Sobczuk, P.
    Bylina, E.
    Klimczak, A.
    Rutkowski, P.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 (07) : S1238 - S1238
12345